NCT02583022

A Study to Evaluate the Safety and Efficacy of PAC-14028 Cream in Atopic Dermatitis

A Randomized, Open-label, Single Center, Investigator-initiated Clinical Study to Evaluate the Safety and Efficacy of PAC-14028 Cream in Subjects With Mild to Moderate Atopic Dermatitis

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 74 (actual)
• Sponsor: Amorepacific Corporation · Industry
• Sex: All
• Age: 20 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

The study is a Phase II, single center, randomized, open-label, placebo-controlled study in male and female subjects, aged ≥ 20 years with mild to moderate atopic dermatitis. All subjects will receive BID topical applications of PAC-14028 cream or vehicle or Elidel cream for up to 4 weeks.

Conditions

• Atopic Dermatitis

Interventions

Type	Name	Description
DRUG	PAC-14028 cream 1.0%	Topical application
DRUG	PAC-14028 cream vehicle	Topical application
DRUG	Elidel cream 1%	Topical application

Timeline

• Start date: 2013-06-01
• Primary completion: 2014-01-01
• Completion: 2015-08-01
• First posted: 2015-10-21
• Last updated: 2015-10-21